Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Злокачественное новообразование бронхов и легкого

Список литературы

  1. Давыдов М.И., Полоцкий Б.Е. Рак легкого. М.: Радикс, 1994.
  2. Трахтенберг А.Х., Чиссов В.И. Клиническая онкопульмонология. М.: ГЭОТАР-Медиа, 2000.
  3. The health consequences of smoking: a report of the Surgeon General. Available at: https://www.hhs.gov/surgeongeneral/reports-and-publications/tobacco/consequences-smoking- factsheet/index.html.
  4. Состояние онкологической помощи населению России в 2017 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. Доступно по: http://www.oncology.ru/service/statistics/condition/2017.pdf.
  5. Stahel R., Peters S., Garassino M. Thoracic tumours essentials for clinicians. ESMO Press, 2014.
  6. WHO classification of tumours of the lung, pleura, thymus and heart 2015.
  7. The AJCC Cancer staging manual. Eight ed. Springer, 2017.
  8. Grunnet M., Sorensen J.B., Carcinoembrionic antigen (CEA) as a tumor marker in lung cancer. Lung Cancer 2012;76:138–43.
  9. Planchard D., Popat S., Kerr R. et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann of Oncology 2018;29(Suppl. 4):192–234.
  10. NCCN Guidelines. Non-small cell lung cancer, version 7.2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
  11. Travis D.W., Brambilla E., Burke A.P. et al. Classification of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2015.
  12. Lung cancer. Ed. by F.V. Fossella, J.B. Putnam, R. Komaki. NewYork: Springer, 2003.
  13. Schrump D.S., Carter D., Kelsey C.R. et al. Non-small cell lung cancer. In: DeVita, Hellman, and Rosenberg cancer; prinsiples and practice of oncology. Ed. by V.T. DeVita Jr, T.S. Lawrence, S.A. Rosenberg et al. Philadelphia: Lippincott Williams and Wilkins, 2011.
  14. Трахтенберг А.Х., Чиссов В.И., Франк Г.А. Нейроэндокринные опухоли легких. М.: Практическая медицина, 2012.
  15. Аллахвердиев А.К., Давыдов М.М. Торакоскопическая лобэктомия с медиастинальной лимфодиссекцией стандарт в хирургическом лечении больных немелкоклеточным раком легкого Т1–2N0М0. Вопросы онкологии 2015;61(3):413–7.
  16. Higuchi M., Yaginuma H., Yonechi A. et al. Long-term outcomes after video-assisted thoracic surgery (VATS) lobectomy versus lobectomy via open thoracotomy for clinical stage Ia non-small cell lung cancer. J Cardiothorac Surg 2014;9:88–92.
  17. Lindberg K., Nyman J., Riesenfeld Kallskog V. et al. Long-term of a results of prospective trial phase II of medically inoperable stage I NSCLC treated with SBRT – the Nordic experience. Acta Oncol 2015;54:1096–104.
  18. Zhang T., Guo Q., Zhang Y. et al. Meta-analysis of adjuvant chemotherapy versus surgery alone in T2aN0 stage IB non-small cell lung cancer. J Can Res Ther 2018;14:139–44.
  19. Winton T., Livingston R., Johnson D. et al. Vinorelbine plus cisplatinvs observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589–97.
  20. Arriagada R., Dunant A., Pignon J.P. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010;28(1):35–42. doi: 10.1200/JCO.2009.23.2272.
  21. NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375(9722):1267–77.
  22. Aureperin A., Le Pechoux C., Rolland E. et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small cell lung cancer. J Clin Oncol 2010;28:2181–90.
  23. Tsitsias T., Boulemden A., Ang K. et al. The N2 paradox: similar outcomes of pre- and postoperatively identified single-zone N2a positive non-small-cell lung cancer. J Eur Cardiothorac Surg 2014;45:882–7.
  24. Scagliotti G.V., Pastorino U., Vansteenkiste J.F. et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol 2012;30:172–8.
  25. Usami N., Yokoi K., Hasegawa Y. et al. Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial. Int J Clin Oncol 2010;15:583–7.
  26. Pérol M., Chouaid C., Pérol D. et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin- gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2012;30:3516–24.
  27. Gilligan D., Nicolson M., Smith I. et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT2/EORTC 08012 multicentre randomised trial and update of systematic review. The Lancet 2007;369(9577):1929–37. doi: 10.1016/S0140-6736(07)60714-4.
  28. Strauss G.M., Herndon III J.E., Maddaus M.A. et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043–51.
  29. Fossella F., Pereira J.R., von Pawel J. et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small- cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016–24.
  30. Burdett S., Rydzewska L., Tierney J. et al. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2016;10(10):CD002142. doi: 10.1002/ 14651858.CD002142.pub4.
  31. Arriagada R., Bergman B., Dunant A. et al. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350(4): 351–60.
  32. Kreuter M., Vansteenkiste J., Fishcer J.R. et al. Randomized phase 2 trial on refinement of early- stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Ann Oncol 2013;24:986–92.
  33. Curran W.J., Paulus R., Langer C.J. et al. Sequential vs concurrent chemoradiation for stage III non-small-cell lung cancer randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011;103:1452–60.
  34. Pignon J.P., Tribodet H., Scagliotti G.V. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26(21):3552–9.
  35. Gridelli С., Chen T., Ko A. et al. nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial. Drug Des Devel Ther 2018;12:1445–51. doi: 10.2147/DDDT.S155750.
  36. Choy H., Gerber D.E., Bradley J.D. et al. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. Lung Cancer 2015;87:232–40.
  37. Senan S., Brade A., Wang L.H. et al. PROCLAIM: randomized phase III trial of pemetrexed- cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2016;34:953–62.
  38. Albain K.S., Crowley J.J., Turrisi A.T. III et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group Phase II Study, SWOG 9019. J Clin Oncol 2002;20:3454–60.
  39. Bradley J.D., Paulus R., Komaki R. et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015;16:187–99.
  40. Antonia S.J., Villegas A., Daniel D. et al. Durvalumab after chemoradiotherapy in stage III non- small-cell lung cancer. N Engl J Med 2017;377(20):1919–29.
  41. Masters G.A., Temin S., Azzoli C.G. et al. Systemic therapy for stage IV non-small cell lung cancer. American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2015;33:3488–515.
  42. Kerr K.M., Bubendorf L., Edelman M.J. et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 2014;25:1681–90.
  43. Rosell R., Carcereny E., Gervais R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239– 46.
  44. Yang J.C., Wu Y.I., Shuler M. et al. Afatinib versus cisplatin-based chemotherapy for EGFR- mutation-positive lung adenocarcinoma LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomized, phase 3 trials. Lancet Oncol 2015;16:141–51.
  45. Soria J.C., Ohe Y., Vansteenkiste J. et al. Osimertinib in untreated EGFR mutated advanced non- small-cell lung cancer. N Engl J Med 2018;378:113–25.
  46. Solomon B.J., Mok T., Kim D.W. et al. First-line crisotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2013;371:2167–77.
  47. Soria J.C., Tan D.S.W., Chiari R. et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND 4): a randomized, open-label, phase 3 study. Lancet 2017;389:917–29.
  48. Camidge D.R. Updated efficacy and safety data from the global phase III ALEX global study of alectinib (ALC) versus crizotinib (CZ) in untreated advanced ALK+ NSCLC. J Clin Oncol 2018;35(Suppl):9064.89
  49. Planchard D., Smit E.F., Groen H.J.M. et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol 2017;18:1307–16.
  50. Zhao X., Suryawanshi S., Hruska M. et al. Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Annals of Oncology 2017;28(8):2002–8.
  51. Klastersky J., Sculier J.P., Lacroix H. et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer:European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990;8:1556–62.
  52. Frasci G., Comella P., Panza N. et al. Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-Italia. Eur J Cancer 1998;34:1710–4.
  53. Ohe Y., Ohashi Y., Kubota K. et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007;18:317–23.
  54. Sandler A., Gray R., Perry M.C. et al. Paclitaxel-carboplatin alone or with bevacizumab for non- small cell lung cancer. N Engl J Med 2006;355:2542–50.
  55. Scagliotti G.V., Parikh P., von Pawel J. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage NSCLC. J Clin Oncol 2008;26:3543–51.
  56. Danson S., Middleton M.R., O’Byrne K.J. et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and ciplatin in patients with advanced non-small cell lung carcinoma. Cancer 2003;98:542–53.
  57. Barlesi F., Scherpereel A., Rittmeywr A. et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small cell lung cancer: AVAPERL. J Clin Oncol 2013;31:3004–11.
  58. Takagi Y., Hosomi Y., Sunami K. et al. A Prospective Study of Shortened Vitamin Supplementation Prior to Cisplatin–Pemetrexed Therapy for Non-Small Cell Lung Cancer. Oncologist 2014;19(11):1194–9. doi: 10.1634/theoncologist.2014-0221.
  59. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899–909.
  60. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst Rev 2010; (5):CD007309.
  61. Azzolic G., Temin S., Aliff T. et al. 2011 Focused Update of 2009 American Society of Clinical Oncology clinical practice guideline update of chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011;29:3825–31.
  62. D’Addario G., Pintile M., Leighi N.B. et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of published literature. J Clin Oncol 2005;23:2926–36.
  63. Zukin M., Barrios C.H., Pereira J.R. et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 2013;31:2849–53.
  64. Переводчикова Н.И., В.А. Горбунова Руководство по химиотерапии опухолевых заболеваний. М.: Практическая медицина, 2015.
  65. Gridelli C., Perrone F., Gallo C. et al. Chemotherapy in elderly patients with advanced non- small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362–72.
  66. Corre R., Greillier L., Le Caer H. et al. Use of a comprehensive geriatric assessment for the management of elderly patients with advanced nonsmall-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study. J Clin Oncol 2016;34:1476–83.
  67. Henry H.D., Costa I., Goldwasser F. et al. Randomised, double-blind study of denosumab versus zoledronic acid in the treatment skeletal metastases in patients with advanced cancer (excluded breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125–32.
  68. Zatloukal P., Kanitz E., Magyar P. et al Gemcitabine in locally advanced and metastatic non- small cell lung cancer: the Central European phase II study. Lung Cancer 1998;22:243–50.
  69. Perol M., Chouaid C., Perol D. et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin- gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2012;30:3516–24.
  70. Fossella F.V., DeVore R., Kerr R.N. et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354–62.
  71. Fidias P.M., Dakhil S.R., Lyss A.P. et al. Phase III study of immmediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol 2009;27:591–8.
  72. Hanna N.H., Sheperd F.A., Fossella F.V. et al. Randomized phase III study of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589–97.
  73. Rosen L.S., Gordon D., Tchekmedyian N.S. et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small-cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613–21.
  74. Cardenal F., López-Cabrerizon M.P., Antón A. et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999;17(1):12–8.
  75. Chow E., Zeng L., Salvo N. et al. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol) 2012;24:112–24.
  76. Reck M., Rodriguez-Abreu D., Robinson A.G. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823–33. doi: 10.1056/NEJMoa1606774.
  77. Lopes G., Wu Y.-L., Kudaba I. et al. Pembrolizumab versus platinum-based chemotherapy as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score ≥1 %: open-label, phase 3 KEYNOTE-042 study. J Clin Oncol 2018;36(18 Suppl).
  78. Langer C.J., Gadgeel S.M., Borghaei H. et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016;17(11):1497–508.
  79. Paz-Ares L., Luft A., Vicente D. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018;379(21):2040–51.
  80. Socinski M.A., Jotte R.M., Cappuzzo F. et al. Atezolizumab in first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018;378:2288–301.
  81. Gandhi I., Rodriguez-Abreu D., Gadgeel S. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:2078–92.
  82. Sheperd F.A., Dancey J., Ramlau R. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum – based chemotherapy. J Clin Oncol 2000;18:2095–103.
  83. Brahmer J., Reckamp K.L., Baas P. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123–35.
  84. Borghaei H., Paz-Ares L., Horn L. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627–39.
  85. Rittmeyer A., Barlesi F., Waterkamp D. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255–65.
  86. Herbst R.S., Baas P., Kim D.W. et al. Pembrolizumab versus docetaxel for previously treated, PD- L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540–50.
  87. Herbst R., Garon E., Kim D.-W. et al. OA03.07 KEYNOTE-010: durable clinical benefit in patients with previously treated, PD-L1-expressing NSCLC who completed pembrolizumab. J Thoracic Oncol 2017;12:254–5.
  88. Long G.V., Tykodi S.S., Schneider J.G. et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Annals of Oncology 2018;29(11):2208–13.
  89. Garon E., Reck M., Rodriguez-Abreu D. et al. P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC): Topic: IT/JTO 2017;12(1):S:S1290–91 doi: https://doi.org/10.1016/j.jthе.2016.11.1825.
  90. Morrissey K.M., Marchand M., Patel H. et al. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemother Pharmacol 2019;84(6):1257–67. doi: 10.1007/s00280-019-03954-8. Epub 2019 Sep 21.
  91. Garassino M., Martelli O., Broggini M., Farina G. et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet oncol 2013;14(10):981–8.
  92. Novello S., Kaiser R., Mellengaard A. et al. Analysis of patient-reported outcomes from the LUME-Lung I trial: a randomized, double-blind, placebo-controlled. Phase III study of second line nintedanib in patients non-small-cell lung cancer. Eur J Cancer 2015;51:317–26.
  93. Sculier J.P., Lafitte J.J., Berghmans T. et. al. A phase II trial testing gemcitabine as second-line chemotherapy for non-small-cell lung cancer. The European Lung Cancer Working Party. Lung Cancer 2000;29:67–73.
  94. Ciuleanu T., Stelmakh L., Cicenas S. et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012;13:300–8.
  95. Karampeazis A., Voutsina A., Souglakos J. et al. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer 2013;119:2754–64.
  96. Soria J.C., Felip E., Cobo M. et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 2015;16:897–907.
  97. Planchard D., Popat S., Kerr K. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Suppl 4):iv192–237.
  98. Ahn M.J., Kim S.W., Cho B.C. et al. Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR. Oncologist 2014;19(7):702–3.
  99. Cho B.C., Kim D.W., Bearz A. et al. ASCEND-8 – a randomized phase I study ceritinib 450 mg or 600 mg taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK) rearranged metastatic non-small-cell lung cancer (NSCLC). J Thorac Oncol 2017;12(9):1357–67. doi: 10.1016/j.jtho.2017.07.005.
  100. Inoue A., Kobayashi K., Usui K. et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009;27:1394–400.
  101. Riely G.J., Yu H.A. EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. Clin Cancer Res 2015;21(10):2221–6. doi: 10.1158/1078-0432.CCR-14-3154.
  102. Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–47.
  103. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981;47(1):207–14.
  104. Burroto M., Manasanch E.E., Wilkerson J., Fojo T. Gefitinib and erlotinib in metastatic non- small-cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist 2015;20:400–10.
  105. Sequst L.V., Yang J.C., Yamamoto N. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327–34.
  106. Cross D.A., Ashton S.E., Ghiorghiu S. et al. AZD9291 irreversible EGFR TKI, overcomes T790M- mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4:1046–61.
  107. Oken M.M., Creech R.H., Tormey D.C. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5(6):649–55.
  108. Oxnard G.R., Thress K.S., Alden R.S. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2016;34(28):3375–82. doi: 10.1200/JCO.2016.66.7162.
  109. Shaw A.T., Ou S.H., Bang Y.J. et al. Crizotinib in ROS1-rearranged nonsmall-cell lung cancer. N Engl J Med 2014;371: 1963–71.
  110. Shaw A.T., Yeap B.Y., Solomon B.J. et al. Impact of crisotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls [abstract]. J Clin. Oncol 2011;29(Suppl. 15):7507.
  111. Moro-Sibilot D., Faivre L., Zalcman G. et al. Crizotinib in patients with advanced ROS1- rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSE phase II trial. J Clin Oncol 2015;33: abstr 8065.
  112. Mazieres J., Zalcman G., Crino L. et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol 2015;33:992–9.
  113. Pan J. Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report. Clinical Drug Investigation 2019;39:1003–7.
  114. Planchard D., Smit E.F., Groen H.J.M. et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol 2017;18:1307–16.
  115. Planchard D., Besse B., Groen H.J.M. et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic nonsmall cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 2016;17(7):984–93.
  116. Planchard D., Smit E.F., Groen H.J.M. et al. Updated survival of patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D+ trametinib (T) in the phase II BRF113928 study. J Clin Oncol 2017;35(Suppl.);аbstract 9075.
  117. Butts C.A., Ding K., Seymour L. et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010;28:29–34.
  118. Sandler A., Yi J., Dahlberg S. et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacisumab with paclitaxel/carboplatin for advanced non- small-cell lung cancer. J Thorac Oncol 2010;5:1416–23.
  119. Yang B., Lee H., Um S.W. et al. Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations. Lung Cancer 2019;129:28–34.
  120. Patchell R.A., Tibbs P.A., Walsh J.W. et al. A randomized trial of surgery in the treatment of single metastases to the brain. New Engl J Med 1990;322:494–500.
  121. Noordijk E.M., Vecht C.J., Haaxma-Reiche H. et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994;29:711–7.
  122. Sahgal A., Aoyama H., Kocher M. et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data of meta- analysis. Int J Radiat Oncol Biol Phys 2015;91:710–7.
  123. Priestman T.J., Dunn J., Brada M. et al. Final results of the Royal College of Radiologists’ Trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol 1996;8:308–15.
  124. Batchelor T., DeAngelis L.M. Medical management of cerebral metastases. Neurosurg Clin North Am 1996;7:435–46.
  125. Naruke T. Lymph node metastasis of lung cancer and associated surgery. Asian Med J 1990;33(12):668–77.
  126. Paul S., Altorki N.K., Sheng S. et al. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS Database. J Thorac Cardiovasc Surg 2010;139:366–78.
  127. Scott W.J., Allen M.S., Darling G. et al. Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Sugeons Oncology Group Z0030 randomised clinical trial. J Thorac Cardiovasc Surg 2010;139:976–81.
  128. Ginsberg R.J., Rubinstein L.V. Randomised trial of lobectomy versus limited resection for Т1N0 non-small cell lung cancer. Ann Thorac Surg 1995;60:615–22.
  129. Schreiber D., Rineer J., Weedon J. et al. Survival outcomes with the use of surgery in limited- stage small cell lung cancer: should its role be re-evaluated? Cancer 2010;116(5):1350–7.
  130. Мелкоклеточный рак легкого. Под ред. М.Б. Бычкова. М.: Фармарус принт Медиа, 2013.
  131. De Ruysscher D., Pijls-Johannesma M., Vansteenkiste J. et al. Systematic review and meta- analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 2006;17:543–52.
  132. Turrisi A.T., Kim K., Blum R. et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265–71.
  133. Zatloukal P., Cardenal F., Szczesna A. et al A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease Ann Oncol 2010;21(9):1810–6.
  134. Rossi A., Di Maio M., Chiodini P. et al. Carboplatin- or cisplatin-based chemotherapy in first- line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012;30(14):1692–8.
  135. Horn L., Mansfeld A.S., Szczęsna A. et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018;379:2220–9.
  136. Von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17(2):658–67.
  137. Morise M., Niho S., Umemura S. et al. Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer. Jpn J Clin Oncol. 2014;44(9):846–51. doi: 10.1093/jjco/hyu094. Epub 2014 Jul 23.
  138. Yamamoto N., Tsurutani J., Yoshimura N. et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res. 2006;26(1B):777–81.
  139. Smit E., Fokkema E., Biesma B. et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 1998;77(2):347–51.
  140. Slotman B., Faivre-Finn C., Kramer G. et al. EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357(7):664–72.
  141. Slotman B.J., van Tinteren H., Praag J.O. et al. Use of thoracic radiotherapy for extensive stage small cell lung cancer: a phase 3 randomised controlled trial. Lancet 2015;385:36–42.
  142. Sommer M.S., Trier K., Vibe-Petersen J. et al. Perioperative rehabilitation in operation for lung cancer (PROLUCA) – rationale and design. BMC Cancer 2014;14:404. doi: 10.1186/1471-2407-14- 404.
  143. Sebio R., Yáñez-Brage M.I., Giménez-Moolhuyzen E. et al. Impact of a pre-operative pulmonary rehabilitation program on functional performance in patients undergoing video- assisted thoracic surgery for lung cancer. Arch Bronconeumol 2016;52(5):231–2.
  144. Sebio G.R., Yáñez Brage M.I., Giménez Moolhuyzen E. et al. Functional and postoperative outcomes after preoperative exercise training in patients with lung cancer: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg 2016;23(3):486–97.
  145. Barassi G., Bellomo R.G., Di Iulio A. et al. Preoperative rehabilitation in lung cancer patients: yoga approach. Adv Exp Med Biol 2018;1096:19–29.
  146. Rogers L.J., Bleetman D., Messenger D.E., Joshi N.A. et al. The impact of enhanced recovery after surgery (ERAS) protocol compliance on morbidity from resection for primary lung cancer. J Thorac Cardiovasc Surg. 2018;155(4):1843–52.
  147. Li S., Zhou K., Che G. et al.Enhanced recovery programs in lung cancer surgery: systematic review and meta-analysis of randomized controlled trials. Cancer Manag Res 2017 Nov 16;9:657– 70. doi: 10.2147/CMAR.S150500.
  148. Deng G.E., Rausch S.M., Jones L.W. et. al. Complementary therapies and integrative medicine in lung cancer. diagnosis and management of lung cancer, 3rd ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2013;143(5 Suppl):e420S–36S.
  149. Imperatori A., Grande A., Castiglioni M. et al. Chest pain control with kinesiology taping after lobectomy for lung cancer: initial results of a randomized placebo-controlled study. Interact Cardiovasc Thorac Surg 2016;23:223–30.
  150. Park H., Park J., Woo S.Y. et al. Effect of high-frequency chest wall oscillation on pulmonary function after pulmonary lobectomy for non-small cell lung cancer. Crit Care Med 2012;40(9):2583–9.
  151. Dhillon H.M., van der Ploeg H.P., Bell M.L. et al. The impact of physical activity on fatigue and quality of life in lung cancer patients: a randomised controlled trial protocol. BMC Cancer 2012;12:572.
  152. Schmitz K.H., Courneya K.S., Matthews C. et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010;42:1409–26.
  153. Janssen S.M., Abbink J.J., Lindeboom R., Vliet Vlieland T.P. Outcomes of pulmonary rehabilitation after treatment for non-small cell lung cancer stages I to IIIa: an observational study. J Cardiopulm Rehabil Prev 2017;37(1):65–71.
  154. Sun V., Raz D.J., Ruel N. et al. A multimedia self-management intervention to prepare cancer patients and family caregivers for lung surgery and postoperative recovery. Clin Lung Cancer 2017;18(3):e151–9.
  155. Batty G.D., Russ T.C., Stamatakis E., Kivimäki M. Psychological distress in relation to site specific cancer mortality: pooling of unpublished data from 16 prospective cohort studies. BMJ 2017;356:j108.
  156. Luszczynska A., Pawłowska I., Cieslak R. et al. Social support and quality of life among lung cancer patients: a systematic review. Psychooncology 2013;22(10):2160–8.
  157. Li M., Kennedy E., Byrne N. et al. Systematic review and meta-analysis of collaborative care interventions for depression in patients with cancer. Psycho-Oncology. 2017;26:573–87.
  158. Rivas-Perez H., Nana-Sinkam P. et al. Integrating pulmonary rehabilitation into the multidisciplinary management of lung cancer: a review. Respir Med 2015;109(4):437–42.
  159. Andrea L., Kollasch J., Vandenberg J. et al. A home-based exercise program to improve function, fatigue, and sleep quality in patients with stage IV lung and colorectal cancer: a randomized controlled trial. J Pain Symptom Manage 2013;45:811–21.
  160. Hilliard R.E. Music therapy in hospice and palliative care: a review of the empirical data. Evid Based Complement Alternat Med 2005;2(2):173–8.
  161. Chen H.Y., Li S.G., Cho W.C.S., Zhang Z.J. The role of acupoint stimulation as an adjunct therapy for lung cancer: a systematic review and meta-analysis. BMC Complement Altern Med 2013;13:362.
  162. Streckmann F., Zopf E.M., Lehmann H.C. et al: Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014;44:1289–304.
  163. Muzi J.L., Look R.M., Turner C. et al. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. J Clin Oncol 2012;30(15 Suppl):9019.
  164. Rick O., von Hehn U., Mikus E. et al. Magnetic field therapy in patients with cytostatics- induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. Bioelectromagnetics 2016;38(2):85–94.
  165. Kilinç M., Livanelioglu A., Yildirim S.A., Tan E. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med 2014;46(5):454–60.
  166. Oberoi S., Zamperlini-Netto G., Beyene J. et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One 2014;9(9):e107418.
  167. Ross M., Fischer-Cartlidge E. Scalp cooling: a literature review of efficacy, safety, and tolerability for chemotherapy-induced alopecia. Clin J Oncol Nurs 2017;21(2):226–33.
  168. Hetkamp M., Bender J., Rheindorf N. et al. A Systematic Review of the Effect of Neurofeedback in Cancer Patients. Integr Cancer Ther 2019;18:1534735419832361. doi:10.1177/1534735419832361.
  169. Bade B.C., Thomas D.D., Scott J.B., Silvestri G.A. Increasing physical activity and exercise in lung cancer. reviewing safety, benefits, and application. J Thorac Oncol 2015;10(6):861–71.
  170. Bensadoun R.J., Nair R.G. Low-level laser therapy in the management of mucositis and dermatitis induced by cancer therapy. Photomed Laser Surg 2015;33(10):487–91.
  171. Williams S., Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer 2006;94:372–90.
  172. Karnofsky D.A., Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of chemotherapeutic agents. Edn. Ed. by MacLeod C. New York: Columbia University Press, 1949.191–205 с.
  173. Hendriks L.E.L. et al. Effect of bisphosphonates, denosumab, and radioisotopes on bone pain and quality of life in patients with non–small cell lung cancer and bone metastases: A systematic review. J Thorac Oncol 2016;11(2):155–73.
  174. Ettinger D.S. et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw Harborside Press, LLC, 2017;15(4):504–35.
  175. Rolfo C., Mack P.C., Scagliotti G.V. et al. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol 2018;13(9):1248–68.
  176. Merker J.D., Oxnard G.R., Compton C. et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol 2018;36(16):1631–41.
  177. Oxnard G.R., Thress K.S., Alden R.S. et al. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2016;34(28):3375–82.
  178. Sacher A.G., Paweletz C., Dahlberg S.E. et al. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol 2016;2(8):1014–22.
  179. Kate S., Chougule A., Joshi A. et al. Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis. Lung Cancer (Auckl) 2019;10:1–10.
  180. Cho J.H., Lim S.H., An H.J. et al. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15- 09). J Clin Oncol 2020;38(5):488–95.
  181. Zhang T., Wan B., Zhao Y. et al. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res 2019;8(3):302–16.
  182. Passaro A., Pochesci A., Spitaleri G. et al. Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7. J Thorac Dis 2016;8(3):E217–E220.
  183. Takeda Y., Naka G., Yamaguchi Y. et al. Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non- small-cell lung cancer patients harboring EGFR mutations. BMC Cancer 2020;20(1):951. doi: 10.1186/s12885-020-07424-w.
  184. NCCN Guidelines. Non-small cell lung cancer, version 6.2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf.
  185. Chan T.A., Yarchoan M., Jaffee E. et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 2019;30(1):44–56.
  186. Luchini C., Bibeau F., Ligtenberg M.J.L. et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30(8):1232– 43.
  187. Merino D.M., McShane L.M., Fabrizio D. et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer.
  188. Vokes N.I., Liu D., Ricciuti B. et al. Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol 2019;3:10.1200/PO.19.00171.
  189. Rosenberg J.E., Hoffman-Censits J., Powles T. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387(10031): 909–20.
  190. Chalmers Z.R., Connelly C.F., Fabrizio D. et al. Analysis of 100, 000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017; 9(1):34.
  191. Kowanetz M., Zou W., Shames D.S. et al. Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC. Ann Oncol 2016; 27(Suppl 6). doi: 10.1093/ annonc/mdw363.25.
  192. Ramalingam S., Hellmann M.D., Awad M.M. et al. Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab + ipilimumab in first-line non-small cell lung cancer: identification of TMB cutoff from Checkmate 568. In AACR Annual Meeting 2018; Abstract #11317.
  193. Balar A.V., Galsky M.D., Rosenberg J.E. et al. Atezolizumab as first-line treatment in cisplatin- ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389(10064): 67–76.
  194. Powles T., Durán I., van der Heijden M.S. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. In: 2018 Genitourinary Cancer Symposium. Lancet 2018;391(10122):748–57. doi: 10.1016/S0140-6736(17)33297-X.
  195. Dietel M., Bubendorf L., Dingemans A.M. et al. Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax 2016;71:177.
  196. Postmus P.E., Kerr K.M., Oudkerk M. et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017,28(Suppl. 4): iv1–iv21.
  197. Soffietti R., Abacioglu U., Baumert B. et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). 2017;19(2),162–74.
  198. De Wever W. Role of integrated PET/CT in the staging of non-small cell lung cancer. JBR-BTR 2009;92:124.
  199. Silvestri G.A., Gonzalez A.V., Jantz M.A. et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of chest physicians evidence- based clinical practice guidelines. Chest 2013;143(5) (Suppl):e211S–e250S. doi.org/10.1378/chest.12-2355 .
  200. National Lung Screening Trial Research Team; Aberle DR, Berg CD., Black W.C. et al. The National Lung Screening Trial: overview and study design. Radiology 2011;258(1):243–53. doi: 10.1148/radiol.10091808. Epub 2010 Nov 2.
  201. National Lung Screening Trial Research Team, Church T.R., Black W.C., Aberle D.R. et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 2013;368:1980. PMID: 23697514.
  202. de Koning H.J., van der Aalst C.M., de Jong P.A. et al. Reduced Lung–Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med 2020;382(6):503–13.
  203. Sadate A., Occean B.V., Beregi J.P. et al. Systematic review and meta-analysis on the impact of lung cancer screening by low-dose computed tomography. Eur J Cancer 2020;134:107.
  204. Herbst R.S., Tsuboi M., John T. et al. Osimertinib as adjuvant therapy in patients with stage IB–IIIA EGFR mutation-positive NSCLC after complete tumor resection: ADAURA. J Clin Oncol 2020;38(suppl 18):LBA5. doi: 10.1200/JCO.2020.38. 18_suppl.LBA5.
  205. Vokes E.E., Herndon J.E., Kelley M.J. et al. (). Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007;25(13): 1698–1704.
  206. Ahn J.S., Ahn Y.C., Kim J.H. et al. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. J Clin Oncol 2015;33(24):2660– 6. doi:10.1200/JCO.2014.60.0130.
  207. Ou S.H., Kwak E.L., Siwak-Tapp C. et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011;6(5):942–6.
  208. Camidge R.D., Ou S.-H.I., Shapiro G. et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer. J Clin Oncol 2014;32(Suppl 5): abstr. 8001.
  209. Li B.T., Shen R., Buonocore D. et al. Ado-Trastuzumab Emtansine for Patients With HER2- Mutant Lung Cancers: Results From a Phase II Basket Trial. [published correction appears in J Clin Oncol 2019;37(4):362]. J Clin Oncol. 2018;36(24):2532–7.
  210. Hellmann M.D., Ciuleanu T.E., Pluzanski A. et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med 2018;378(22):2093–104.
  211. Carbone D.P., Reck M., Paz-Ares L. et al. First-Line Nivolumab in Stage IV or Recurrent Non- Small-Cell Lung Cancer. N Engl J Med 2017;376(25):2415–426.
  212. Drilon A., Wang L., Hasanovic A. et al. Response to Cabozantinib in patients with RET fusion- positive lung adenocarcinomas. Cancer Discov 2013;3(6):630–5.
  213. Lee S.H., Lee J.K., Ahn M.J., et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. Ann Oncol 2017;28(2):292– 7.
  214. Drilon A., Clark J.W., Weiss J. et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med 2020;26(1):47–51.
  215. Spigel D., De Marinis F., Giaccone G.et al. IMpower110: Interim OS Analysis of a Phase III Study of Atezolizumab (atezo) vs Platinum-Based Chemotherapy (chemo) as 1L Treatment (tx) in PD-L1–selected NSCLC// ESMO 2019 (Abs LBA78). Ann Oncol. 2019;30(suppl_5):v851–v934. doi: 10.1093/annonc/mdz394.
  216. Herbst R.S., de Marinis F., Giaccone G. et al. Clinical efficacy of Atezolizumab (Atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunochistochemistry (IHC) assys and by blood tumor mutational burden (BTMB): results from the IMPOWER110 study// ESMO IO 2019 (Abs LBA1).
  217. Официальная инструкция по применению препарата. Доступно по: https://back-grls.pharm-portal.ru/storage/instructions/%D0%9B%D0%9F004652/ InstrImg_0001458248_0000609663/%D0%9B%D0%9F-004652[2020]_1.pdf.
  218. Chou C.H., Hsu L.F. Model-based simulation to support the extended dosing regimens of atezolizumab. Eur J Clin Pharmacol 2020 Aug 17 [Online ahead of print]. doi: 10.1007/s00228-020- 02980-3. Epub ahead of print. PMID: 32808071.
  219. Hellman M.D, Paz-Ares L., Caro R.B. et al. Nivolumab plus Ipilimumab in Advanced Non– Small-Cell Lung Cancer. N Engl J Med 2019; 381:2020–31.
  220. Reck M., Ciuleanu T.-D., Dols M.C. et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. J Clin Oncol 2020;38(15):9501.
  221. Lala M., Li T.R., de Alwis D.P., Sinha V. et al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur J Cancer 2020;131:68–75. doi: 10.1016/j.ejca.2020.02.016. Epub 2020 Apr 15. PMID: 32305010.
  222. Grohe C., Gleiber W., Haas S. et al. Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma. Future Oncol, Epub online:8 Jul 2019, doi: 10.2217/fon-2019-0262; 2019. p. 2699-2706.
  223. Nakagawa K., Garon E., Seto T. et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20(12):1655–69.
  224. Garon E., Ciuleanu T.-E., Arrieta O. et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384(9944):665–73.
  225. Stinchcombe T.E., Jänne P.A., Wang X. et al. Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer: A phase 2 randomized clinical trial. JAMA Oncol 2019;5(10):1448–55. doi.org/10.1001/jamaoncol.2019.1847.
  226. Mok T., Camidge D.R., Gadgeel S.M. et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol 2020;31(8):1056–64. doi: 10.1016/j.annonc.2020.04.478. Epub 2020 May 11.
  227. Paz-Ares L. Dvorkin M., Chen Y., Reinmuth N. Durvalumab ± tremelimumab + platinum- etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study. J Clin Oncol 2020;38:15_suppl, 9002. doi: 10.1200/JCO.2020.38.15_suppl.9002.
  228. Chen Y., Paz-Ares L., Dvorkin M. et al. First-line durvalumab plus platinum-etoposide in ES- SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes. J ClinOncol 2020;38:15_suppl: 9068. doi: 10.1200/JCO.2020.38. 15_suppl. 9068.
  229. NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer Version 3.2020,02/05/2020. URL: www.nccn.org/professionals/physician_gls/pdf/sclc.pdf.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*